Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

The severity of left ventricular diastolic dysfunction affects risk for incident stroke and transient ischemic attack, as well as major bleeding.

The primary end point was major or clinically relevant nonmajor bleeding. The researchers found that the median reduction in free factor XI levels was 99% and 97% with abelacimab at a dose of ...

Professor Karim Brohi and his colleagues have developed new treatment approaches for trauma patients with critical bleeding that have reduced death rates by nearly 30% percent at the Royal London ...